Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
T Cell Types and Functions01:24

T Cell Types and Functions

1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis.

PloS one·2026
Same author

Clinical utility of immune biomarker staining of skin biopsies in psoriasis and eczematous dermatitis: A single-center retrospective analysis.

Journal of the American Academy of Dermatology·2026
Same author

Atopic Dermatitis and Celiac Disease: A Study of US Adults in the NIH All of US Research Program.

International journal of dermatology·2026
Same author

Association of psychiatric comorbidity with worse quality of life despite clear or almost clear skin.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

RNA in situ hybridization for ISG15 and IFI6 highlights IFN-I activity in discoid lupus erythematosus.

JID innovations : skin science from molecules to population health·2026
Same author

Pustular Dermatoses. Part II. Infectious, Genetic, and Transient Neonatal.

Journal of the American Academy of Dermatology·2026
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Biologics for Psoriasis.

Anthony Mitchel Wride1, Gloria F Chen1, Sarah L Spaulding1

  • 1Department of Dermatology, Yale School of Medicine, Yale University, 15 York Street, New Haven, CT 06510, USA.

Dermatologic Clinics
|May 25, 2024
PubMed
Summary
This summary is machine-generated.

Biologic therapies, including IL-23 inhibitors like risankizumab, have transformed psoriasis treatment. IL-23 inhibitors demonstrate superior efficacy and safety compared to other biologics, offering the best long-term risk-benefit profile.

Keywords:
BiologicsEfficacyPsoriasisSafety

More Related Videos

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

14.6K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

377

Related Experiment Videos

Last Updated: Jun 25, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K
Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture
10:31

Lymphocyte Isolation from Human Skin for Phenotypic Analysis and Ex Vivo Cell Culture

Published on: April 8, 2016

14.6K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

377

Area of Science:

  • Dermatology and immunology
  • Pharmacology and therapeutics

Background:

  • Biologic therapies have significantly advanced psoriasis management.
  • Targeting specific cytokines like TNF-α, IL-12/23, IL-23, and IL-17 has revolutionized treatment approaches.

Purpose of the Study:

  • To compare the efficacy and safety of various biologic therapies for psoriasis.
  • To evaluate the long-term risk-benefit profiles of different biologic classes.

Main Methods:

  • Review of biologic therapies including TNF-α, IL-12/23, IL-23, and IL-17 inhibitors.
  • Analysis of Psoriasis Area and Severity Index (PASI) 90 scores for treatment efficacy.
  • Assessment of short-term and long-term adverse event rates.

Main Results:

  • Risankizumab (an IL-23 inhibitor) achieved the highest PASI 90 scores compared to other biologics.
  • IL-23 inhibitors exhibited the lowest rates of adverse events.
  • IL-23 inhibitors demonstrated the most favorable long-term risk-benefit profile.

Conclusions:

  • IL-23 inhibitors represent a highly effective and safe treatment option for psoriasis.
  • Risankizumab shows superior efficacy in achieving significant skin clearance.
  • Biologics targeting IL-23 offer an optimal balance of efficacy and safety for long-term psoriasis management.